Value After Hours Podcast feat. David Ferreiro, Ph.D.

Podcast
November 2026

In a Value: After Hours Podcast, David Ferreiro, Ph.D., Portfolio Manager at TimesSquare, discusses the firm's quality growth approach to small cap investing, identifying opportunities in biotech and healthcare, and the evolving role of artificial intelligence in drug development.

Overview

In an interview on the Value: After Hours podcast with hosts Tobias Carlisle and Jake Taylor, David Ferreiro, Ph.D., Portfolio Manager & Research Analyst at TimesSquare, discusses the firm’s quality growth approach to small cap investing, how TimesSquare defines quality in biotech and broader healthcare, and where artificial intelligence is, and is not yet, changing drug development.

Drawing on his background as a scientist, David explains how TimesSquare pairs rigorous fundamental research with strong management teams, disciplined position sizing, and price-target-driven sell discipline to take educated risks in healthcare while managing downside.

‍

Timestamped Sections

0:01 – 3:21 | Quality With A Conscience

Summary

David explains TimesSquare’s vehicle-agnostic, quality growth approach, which starts with the merits of the business and its management team before turning to valuation.

Key Takeaways

  • TimesSquare looks for sustainable competitive advantages, such as proprietary products, barriers to entry, and intellectual property moats, alongside a strong, consistent growth profile.
  • Management quality is a key determinant of success, especially in small caps, and TimesSquare sets upside, downside, and base case price targets to guide entry and exit points.

‍

3:21 to 7:08 | From Scientist to Stock Picker

Summary

David describes his path from a Ph.D. in microbiology and immunology to the sell side and ultimately the buy side, and how scientific training shapes his investment process.

Key Takeaways

  • Fluency in the language of science and medicine helps translate complex healthcare developments into investment ideas.
  • Scientific training instills analytical rigor and healthy skepticism, encouraging deeper research before reaching conclusions.

‍

7:08 to 12:28 | Defining Quality in Biotech

Summary

Using Mirum Pharmaceuticals as an example, David outlines how TimesSquare applies its quality lens to biotech by favoring later-stage and commercial companies.

Key Takeaways

  • TimesSquare generally begins its biotech research at the Phase 2 stage, after early proof of concept, and leans toward companies that are commercial or near commercialization.
  • An established commercial business provides a fallback while a diversified pipeline and disciplined management team create multiple opportunities for upside.

‍

12:28 to 16:01 | Where the Market Misprices Healthcare

Summary

David discusses why opportunities persist in biotech, pointing to uncertainty around rare disease markets and the inherent unpredictability of biology.

Key Takeaways

  • Rare disease markets can prove larger than expected, particularly when assets were under-resourced by their previous owners.
  • Clinical development carries genuine idiosyncratic risk, creating opportunities to be rewarded for taking educated risks where outcomes are hard to predict.

‍

16:01 to 21:03 | Balancing Risk Through Position Sizing

Summary

David explains how TimesSquare sizes healthcare positions according to their risk profile while maintaining a diversified portfolio.

Key Takeaways

  • Companies with profitable commercial businesses can become larger positions, while binary, single-asset bets are kept meaningfully smaller.
  • The small cap strategy typically holds 75 to 100 positions, supported by a team-based approach in which sector specialists cover healthcare and other sectors.

‍

21:03 to 24:33 | Rates, Rotation, and Healthcare Valuations

Summary

David examines how interest rates and recent market rotation have affected healthcare, and where valuations look compelling.

Key Takeaways

  • Long-duration healthcare assets tend to move inversely with yields, and in a higher-rate environment investors have favored commercial-stage companies over developmental ones.
  • Medical devices recently traded near historically low valuations, and some companies’ pipelines appear to be meaningfully discounted by the market.

‍

24:33 to 40:04 | AI in Drug Development: Promise vs. Reality

Summary

David assesses AI’s impact on biopharma, noting meaningful efficiency gains in early-stage discovery but limited progress so far in improving the underlying biology.

Key Takeaways

  • Ai has accelerated molecule design and early clinical progress, real productivity gains on the developmental side; the time from idea to drug has sped up. This has not yet improved success rates from Phase 2 to Phase 3, where efficacy is proven.
  • Patient selection and trial enrollment are promising areas for AI, though long-duration trials remain constrained by the time needed to observe outcomes.

‍

40:05 to 43.39 | Price Targets Drive Sell Discipline

Summary

David details how upside, downside, and base case price targets inform TimesSquare’s sell decisions.

Key Takeaways

  • A breach of the downside price target is often a signal that the original investment thesis has broken.
  • When targets are met, the team may aggressively trim positions, recycling capital into a steady flow of new ideas rather than holding stocks too long.

‍

43:40 to 48:34 | Why Clinical Trials Are So Costly

Summary

David breaks down the drivers of clinical trial costs, from intensive patient monitoring to complex global logistics.

Key Takeaways

  • Multi-year studies across many sites and countries, frequent testing, and drug manufacturing all add up, alongside the need for a complete and auditable dataset.
  • More precise patient selection, potentially aided by AI, could allow smaller trials and help bring costs down over time.

‍

48:34 to 50:54 | What Acquired Companies Have in Common

Summary

David highlights the characteristics frequently shared by biopharma companies that are acquired, including names that have come out of TimesSquare’s portfolio.

Key Takeaways

  • Acquired assets often feature clean data packages, address areas of unmet medical need, and are first-in-class or novel rather than incremental therapies.
  • Strong management teams capable of navigating the development pathway are as important as the asset itself.

‍

50:54 to 56:43 | Building a Durable Drug Franchise

Summary

Responding to a listener question on Revolution Medicines, David discusses what it takes for a breakthrough therapy to sustain growth and how long drug exclusivity typically lasts.

Key Takeaways

  • Long-term growth depends on moving into earlier lines of treatment and expanding into new indications beyond an initial approval.
  • Drugs typically enjoy roughly 10 years of exclusivity, so successful companies continually build their pipelines to avoid a single-asset patent cliff.

‍

56:43 to 1:00:00 | Renewed Opportunity in Medtech

Summary

David explains why TimesSquare has grown more constructive on medical technology after a period when investors avoided the sector amid GLP-1 enthusiasm.

Key Takeaways

  • Concerns that GLP-1 drugs would sharply reduce demand for cardiovascular, orthopedic, and sleep apnea procedures have faded, leaving valuations at historically attractive levels.
  • Public medtech companies generally have real revenues, and TimesSquare favors high-tech businesses with deep regulatory moats and limited competition.

‍

Bottom Line

TimesSquare’s approach to small cap healthcare investing combines scientific expertise, independent fundamental research, and a disciplined framework for sizing and exiting positions. By favoring high-quality businesses with strong management teams and real commercial foundations, the firm seeks to take educated risks in areas of innovation while working to deliver attractive long-term, risk-adjusted returns.

‍

Disclosures

Specific investments described herein do not represent all investment decisions made by the Firm. The reader should not assume that investment decisions identified and discussed were or will be profitable. Specific investment advice references provided herein are for illustrative purposes only and are not necessarily representative of investments that will be made in the future.

This podcast does not constitute advice or a recommendation or offer to sell or a solicitation to deal in any security or financial product. It is provided for information purposes only and on the understanding that the recipient has sufficient knowledge and experience to be able to understand and make their own evaluation of the proposals and services described herein; any risks associated therewith; and any related legal, tax, accounting or other material considerations. To the extent that the reader has any questions regarding the applicability of any specific issue discussed above to their specific portfolio or situation, prospective investors are encouraged to contact TimesSquare Capital Management, LLC and/or consult with the professional adviser of their choosing.

The views and opinions expressed by David Ferreiro, Ph.D., during this podcast are those of the speaker and do not necessarily reflect the views, opinions, or investment positions of TimesSquare Capital Management, LLC.

Past performance does not guarantee future results.

Click here for the strategy's Top Ten Holdings.

For the TimesSquare Glossary, please visit here.